Aminacrine
| Evidence Level: L5 | Predicted Indications: 10 |
Table of Contents
Aminacrine: From Topical Antisepsis to Paratyphoid Fever
One-Sentence Summary
Aminacrine (9-aminoacridine) is a topical antiseptic acridine compound, marketed in Singapore as a gel. The TxGNN model predicts it may be effective for paratyphoid fever, but the prediction rests on a computational score alone, with 0 clinical trials and 0 publications supporting it.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not stated in the Singapore licence record (topical antiseptic use is inferred from the drug class) |
| Predicted New Indication | Paratyphoid fever |
| TxGNN Prediction Score | 98.26% |
| Evidence Level | L5 |
| Singapore Market Status | ✓ Marketed |
| Number of Registrations | 1 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available. Based on known information, aminacrine is a topical antiseptic acridine dye with broad antibacterial activity. Mechanistically, antibacterial activity could apply to a bacterial infection such as paratyphoid fever (Salmonella Paratyphi).
There is an important limitation. Paratyphoid fever is a systemic enteric infection. A topical antiseptic is unlikely to reach adequate systemic or intestinal-tissue exposure, and the only registered product is a gel. The prediction should therefore be treated as a computational hypothesis, not a supported therapeutic direction.
Other predictions, in order of score, show the same pattern:
- Bacterial or local infections (sinusitis, chronic ethmoidal sinusitis, apical periodontitis, periapical granuloma, suppurative periapical periodontitis): a local antiseptic effect is conceivable, but none has trial or literature support. Established agents already exist for the dental indications.
- Epiglottitis: an acute, potentially life-threatening infection that needs systemic antibiotics and airway management. A topical antiseptic is not appropriate.
- Chronic rhinosinusitis: largely an inflammatory disease, so the rationale is weak and indirect.
- Diffuse scleroderma: no clear mechanistic link, as it is an autoimmune fibrotic disease.
- Paranasal sinus neoplasm: DNA intercalation by acridines gives only a speculative antiproliferative rationale.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Singapore Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| SIN04748P | MEDIJEL GEL | Gel | Not stated in the licence record |
Aminacrine is available in Singapore only as a topical gel (single-ingredient product, valid licence).
Safety Considerations
- Disease associations flagged in the knowledge graph: The TxGNN knowledge graph links aminacrine to contraindications in the following conditions. These come from graph relationships, not from label text, and should be verified against the package insert:
- Inherited porphyria, porphyrin metabolism disease, and porphyria
- Kidney disease and liver disease
- Hematologic disease
- G6PD deficiency
- Pyoureter and gallbladder disease
- Glycogen storage disease, cystinuria, and galactosemia
- Drug Interactions: No interaction records were found.
Please refer to the package insert for further safety information. Safety data for intranasal, mucosal, intracanal, or systemic use is not available.
Conclusion and Next Steps
Decision: Hold
Rationale: All ten predicted indications have only model-based support (L5), with no registered trials or literature. For paratyphoid fever and epiglottitis in particular, a topical antiseptic is unlikely to be appropriate. The mechanism of action and package insert safety data are also missing.
To proceed, the following is needed:
- Package insert warnings and contraindications from the Singapore regulator (HSA), which currently block safety screening
- Mechanism of action data from DrugBank
- Route-compatibility assessment, since the only registered form is a topical gel and the predicted indications mostly require systemic or deep-tissue exposure
- Literature and trial searches on antiseptic use in the localised infections (sinus and endodontic), which are the most plausible of the predictions
- Safety and tolerability data for any mucosal or intracanal use
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.